More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$28963681
EPS
-1.44
P/E ratio
--
Price to sales
2.11
Dividend yield
--
Beta
1.145149
Previous close
$3.21
Today's open
$3.23
Day's range
$2.84 - $3.23
52 week range
$2.84 - $9.12
show more
CEO
David Angulo
Employees
18
Headquarters
Jersey City, NJ
Exchange
NASDAQ Capital Market
Shares outstanding
9953155
Issue type
Common Stock
Healthcare
Pharmaceuticals
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update highlighting the completion of a Phase 1 study of SCY-770 in support of its planned Phase 2 program in Autosomal Dominant Polycystic Kidney Disease (ADPKD), the award of a BARDA contract providing up to approximately $214 million in non-dilutive funding to advance the development of SCY-247, and the completion of the Phase 1 study of intravenous SCY-247.
GlobeNewsWire • Nov 5, 2026

SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.
GlobeNewsWire • Oct 29, 2026

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant fungi.
GlobeNewsWire • Oct 22, 2026

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, announces that SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate, will be featured in an oral company pipeline presentation at IDWeek, being held October 21-24, 2026 at the Walter E. Washington Convention Center in Washington, D.C. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant fungi.
GlobeNewsWire • Oct 21, 2026

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated
GlobeNewsWire • Oct 6, 2026

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, to advance the development of SCY-247, the Company's second-generation fungerp antifungal candidate.
GlobeNewsWire • Sep 28, 2026

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.
JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K.
GlobeNewsWire • Sep 22, 2026

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D.
GlobeNewsWire • Sep 15, 2026

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies
GlobeNewsWire • Sep 10, 2026

SCYNEXIS to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:
GlobeNewsWire • Sep 1, 2026

¹ Disclosures

Open an M1 investment account to buy and sell SCYNEXIS Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.